Novel biomarkers for potential risk stratification of drug induced liver injury (DILI): A narrative perspective on current trends.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
20
12
2019
pubmed:
20
12
2019
medline:
28
12
2019
Statut:
ppublish
Résumé
Drug induced liver injury (DILI) is an increasing cause of acute liver injury especially with increasing need for pharmacotherapy of widening comorbidities amongst our ever-aging population. Uncertainty however remains regarding both acceptable and widely agreeable diagnostic algorithms as well a clear understanding of mechanistic insights that most accurately underpins it. In this review, we have explored the potential role of emerging novel markers of DILI and how they could possibly be integrated into clinical care of patients. We explored PUBMED and all other relevant databases for scientific studies that explored potential utility of novel biomarkers of DILI, and subsequently carried out a narrative synthesis of this data. As this is a narrative review with no recourse to patient identifiable information, no ethics committee's approval was sought or required. Novel biomarkers such as microRNA-122 (miR-122) profiles, high mobility group box-1 (HMGB1), glutamate dehydrogenase (GLDH), and cytokeratin-18 (K-18), amongst others do have the potential for reducing diagnostic uncertainties associated with DILI. With the increasing validation of some of the novel liver biomarkers such as K-18, mir-122, HMGB-1, and GLDH, there is the potential for improvement in the diagnostic uncertainty commonly associated with cases of DILI.
Sections du résumé
BACKGROUND
BACKGROUND
Drug induced liver injury (DILI) is an increasing cause of acute liver injury especially with increasing need for pharmacotherapy of widening comorbidities amongst our ever-aging population. Uncertainty however remains regarding both acceptable and widely agreeable diagnostic algorithms as well a clear understanding of mechanistic insights that most accurately underpins it. In this review, we have explored the potential role of emerging novel markers of DILI and how they could possibly be integrated into clinical care of patients.
METHODS
METHODS
We explored PUBMED and all other relevant databases for scientific studies that explored potential utility of novel biomarkers of DILI, and subsequently carried out a narrative synthesis of this data. As this is a narrative review with no recourse to patient identifiable information, no ethics committee's approval was sought or required.
RESULTS
RESULTS
Novel biomarkers such as microRNA-122 (miR-122) profiles, high mobility group box-1 (HMGB1), glutamate dehydrogenase (GLDH), and cytokeratin-18 (K-18), amongst others do have the potential for reducing diagnostic uncertainties associated with DILI.
CONCLUSION
CONCLUSIONS
With the increasing validation of some of the novel liver biomarkers such as K-18, mir-122, HMGB-1, and GLDH, there is the potential for improvement in the diagnostic uncertainty commonly associated with cases of DILI.
Identifiants
pubmed: 31852121
doi: 10.1097/MD.0000000000018322
pii: 00005792-201912130-00061
pmc: PMC6922486
doi:
Substances chimiques
Biomarkers
0
HMGB1 Protein
0
HMGB1 protein, human
0
KRT18 protein, human
0
Keratin-18
0
MIRN122 microRNA, human
0
MicroRNAs
0
Glutamate Dehydrogenase
EC 1.4.1.2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e18322Références
J Hepatol. 2013 Oct;59(4):842-58
pubmed: 23714158
Hum Pathol. 2017 Oct;68:92-98
pubmed: 28873351
J Hepatol. 1990 Sep;11(2):272-6
pubmed: 2254635
Eur J Gastroenterol Hepatol. 2005 Feb;17(2):141-3
pubmed: 15674089
J Intern Med. 1996 Mar;239(3):279-81
pubmed: 8772629
Hepatology. 2005 Aug;42(2):481-9
pubmed: 16025496
Hepatology. 2016 Mar;63(3):993-9
pubmed: 26439084
Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12169-74
pubmed: 25092309
J Hepatol. 2012 May;56(5):1070-1079
pubmed: 22266604
Arch Intern Med. 2005 Jun 27;165(12):1363-9
pubmed: 15983284
Clin Pharmacol Ther. 2012 Aug;92(2):214-20
pubmed: 22739141
JAMA. 2006 Jul 5;296(1):87-93
pubmed: 16820551
Hepatology. 2002 Aug;36(2):451-5
pubmed: 12143055
Curr Biol. 2002 Apr 30;12(9):735-9
pubmed: 12007417
Liver Int. 2014 Mar;34(3):367-78
pubmed: 24118944
Gastroenterol Clin North Am. 2017 Jun;46(2):273-296
pubmed: 28506365
Biomark Med. 2013 Jun;7(3):383-6
pubmed: 23734798
Hepatology. 2014 Feb;59(2):661-70
pubmed: 24037963
Arch Intern Med. 1965 Feb;115:128-36
pubmed: 14331990
Gastroenterology. 2005 Aug;129(2):512-21
pubmed: 16083708
Hepatology. 2011 Nov;54(5):1767-76
pubmed: 22045675
Toxicol Sci. 2013 Apr;132(2):276-83
pubmed: 23339181
Lancet Gastroenterol Hepatol. 2018 Feb;3(2):104-113
pubmed: 29146439
Gastroenterology. 2012 Nov;143(5):1158-1172
pubmed: 22982943
Hepatology. 2010 Jun;51(6):2117-26
pubmed: 20512999
Nat Rev Drug Discov. 2005 Jun;4(6):489-99
pubmed: 15931258